IBRX - ImmunityBio, Inc.
NEXT EARNINGS:
Mar 2, 2026
(in 5 days)
EPS Est: $-0.08
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$11.00
DETAILS
HIGH:
$15.00
LOW:
$7.00
MEDIAN:
$11.00
CONSENSUS:
$11.00
DOWNSIDE:
4.76%
Market Cap:
11.38B
Volume:
82,287,047
Avg Volume:
30,229,986
52 Week Range:
1.83-12.28
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.02
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
671
IPO Date:
2015-07-28
EPS (TTM):
-0.38
P/E Ratio:
-5.18
Revenue (TTM):
113.29M
Total Assets:
501.90M
Total Debt:
40.98M
Cash & Equiv:
88.33M
Rev Growth (5Y):
184.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
-0.08
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $-0.07 | $-0.10 | +30.0% | $32.1M | $37.8M | -15.1% |
| 2025-08-05 | $-0.10 | $-0.10 | 0.0% | $26.4M | $31.9M | -17.1% |
| 2025-05-12 | $-0.15 | $-0.12 | -25.0% | $16.5M | $16.6M | -0.5% |
| 2025-03-03 | $-0.15 | $-0.26 | +42.3% | $7.6M | $9.6M | -21.5% |
| 2024-11-12 | $-0.14 | $-0.18 | +22.2% | $6.1M | $9.1M | -32.7% |
| 2024-08-12 | $-0.20 | $-0.17 | -17.6% | $1.0M | $2.5M | -58.5% |
| 2024-05-09 | $-0.20 | $-0.16 | -25.0% | $40000 | $20000 | +100.0% |
| 2024-03-19 | $-0.19 | $-0.18 | -5.6% | $139000 | $20000 | +595.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.29M | 14.74M | 622,000 | 240,000 | 934,000 | 605,000 | 43,000 | 47,000 | 45,000 | 44,000 | 236,000 | 641,000 |
| Net Income | (351.40M) | (413.56M) | (583.20M) | (416.57M) | (346.79M) | (221.85M) | (65.79M) | (96.23M) | (96.42M) | (120.81M) | (236.88M) | (6.21M) |
| EPS | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 | -0.59 | -0.42 | -0.30 | -0.30 | -0.37 | -0.73 | -0.02 |
| Total Assets | 501.90M | 382.93M | 504.45M | 362.36M | 468.91M | 221.38M | 143.12M | 181.95M | 250.44M | 317.50M | 366.85M | 60.83M |
| Total Debt | 40.98M | 504.17M | 726.72M | 723.77M | 645.66M | 275.55M | 14.85M | 6.91M | 7.27M | 8.21M | 2.47M | 265,000 |
| Cash & Equivalents | 88.33M | 143.43M | 265.45M | 104.64M | 181.10M | 34.91M | 15.51M | 16.82M | 23.87M | 8.08M | 175.91M | 59.10M |
| Operating Cash Flow | (304.94M) | (391.24M) | (366.76M) | (337.51M) | (274.42M) | (171.72M) | (152.11M) | (63.38M) | (48.78M) | (38.59M) | (25.30M) | (5.35M) |
| Free Cash Flow | (304.94M) | (398.12M) | (397.34M) | (415.67M) | (307.98M) | (173.39M) | (156.40M) | (76.48M) | (83.59M) | (45.15M) | (27.55M) | (5.65M) |
| FCF per Share | -0.33 | -0.57 | -0.78 | -1.04 | -0.79 | -0.45 | -0.41 | -0.24 | -0.26 | -0.14 | -0.08 | -0.02 |
| Book Value | (499.57M) | (489.10M) | (586.99M) | (447.33M) | (242.17M) | (119.81M) | 120.68M | 146.01M | 218.84M | 293.42M | 356.00M | 58.42M |
| Cash & ST Investments | 242.82M | 149.81M | 266.46M | 107.18M | 317.12M | 96.06M | 51.65M | 74.15M | 128.15M | 198.92M | 294.22M | 59.10M |
| ROC Equity | N/A | N/A | N/A | N/A | N/A | N/A | -0.55 | -0.66 | -0.44 | -0.41 | -0.67 | -0.11 |